Chest Pain

Disease

Related News

Mavacamten Shows Promise for Adolescents with Hypertrophic Cardiomyopathy

Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.

Related Clinical Trials

NCT ID Title Status Phase
NCT07727590

ER-VISION-AI Study

NOT_YET_RECRUITING NA
NCT07653204

Contactless Ultrasound Data Acquisition in Emergency Departments to Discriminate the Origin of Dyspnea and Chest Pain

NOT_YET_RECRUITING
NCT07620119

Machine Learning for Diagnosis of Occlusive MI in LBBB Patients

RECRUITING
NCT07579182

Hormones, Outcomes, and Pain Pathways in Exercise Study

RECRUITING PHASE1
NCT07536932

Triage and Recognition of Acute Aortic Dissection in Chest Pain by Electrocardiogram-Artificial Intelligence

NOT_YET_RECRUITING
NCT07532564

Risk Factors, Costs, and Impacts of ED Boarding

COMPLETED
NCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

RECRUITING NA
NCT07432620

Artificial Intelligence Stress Echo (FINESSE) Project

ACTIVE_NOT_RECRUITING
NCT07258290

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

RECRUITING NA
NCT07247669

Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).

RECRUITING